Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039778 · ClinicalTrials.gov registry record · NA
Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma
A NA study, sponsored by Beth Israel Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02039778: Clinical Trial NA study, sponsored by Beth Israel Medical Center.
NCT02039778 is a NA study that was terminated before completion, run by Beth Israel Medical Center. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02039778, a NA study, was terminated before completion, sponsored by Beth Israel Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
There are preliminary studies that suggest that radiation therapy to areas of the brain containing cancer stem cells (in addition to the area where the tumor was surgically treated) may help patients with high-grade brain tumors live longer. The purpose of this study is to determine whether the addition of stem-cell radiation therapy to the standard chemoradiation will further improve the outcome. The investigators will collect information about the patient's clinical status, disease control, neurocognitive effects, and quality of life during follow-up in our department. The purpose of the study is to improve the overall survival patients with newly diagnosed malignant brain tumors treated with stem cell radiation therapy and chemotherapy. The investigators will also measure how patients treated with this novel method of radiation therapy do over time in terms of disease control, potential neurocognitive side effects, overall function, and quality of life.
Primary Outcome
The overall survival of patients with newly diagnosed high-grade glioma (HGG) treated with concurrent ScRT and temozolomide, followed by post-radiation temozolomide (and compare to historical controls).
Interventions
- RADIATION Stem Cell Radiotherapy (ScRT) and Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-12 |
| Phase | NA |
Why NCT02039778 stopped before completion
NCT02039778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Stem Cell Radiotherapy (ScRT) and Temozolomide is the first listed.
NCT02039778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02039778 about?
NCT02039778 is a clinical study titled "Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma". There are preliminary studies that suggest that radiation therapy to areas of the brain containing cancer stem cells (in addition to the area where the tumor was surgically treated) may help patients with high-grade brain tumors live longer. The purpose of this study is to determine whether the addi...
What is the current status of trial NCT02039778?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2013-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02039778?
The interventions under investigation include: Stem Cell Radiotherapy (ScRT) and Temozolomide (RADIATION).
Who is sponsoring clinical trial NCT02039778?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02039778's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia